Orion Pharma Ltd.

Angimet MR 35 mgAngimet MR 35 mg is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugsPharmacologyAngimet MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Angimet MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.Dosage & Administration of Angimet MR 35 mgThe recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Dosage of Angimet MR 35 mgThe recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.Interaction of Angimet MR 35 mgNo drug interaction so far has been reported. In particular, no interaction has been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.ContraindicationsTrimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson?s disease, parkinsonian symptoms, tremors, restless legs movement disorders, severe renal impairment.Side Effects of Angimet MR 35 mgTrimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and astheniaPregnancy & LactationThere is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.Precautions & WarningsTrimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is also not a treatment for myocardial infarction.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Drug ClassesOther Anti-anginal & Anti-ischaemic drugsMode Of ActionAngimet MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Angimet MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.PregnancyThere is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.

Avison 1%+0.1%Econazole Nitrate & Triamcinolone Acetonide indicated for the treatment of: Eczematous Mycoses Psoriasis Tinea Pedis (Athlete?s foot) Tinea Corporis (Ring worm) Tinea Cruris (Jock itch) Inflammatory Intertrigo Diaper Dermatitis ... Read moreEconazole Nitrate & Triamcinolone Acetonide indicated for the treatment of: Eczematous Mycoses Psoriasis Tinea Pedis (Athlete?s foot) Tinea Corporis (Ring worm) Tinea Cruris (Jock itch) Inflammatory Intertrigo Diaper Dermatitis Onychomycoses- for the treatment of onychomycoses, local therapy with Econazole/Triamcinolone cream, combined with an oral antimycotic, is recommended.Theropeutic ClassTriamcinolone & Combined preparationsPharmacologyEconazole Nitrate: Econazole modifies the permeability of cell wall membrane in fungi; may interfere with RNA and protein synthesis, and lipid metabolism.Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.Dosage & Administration of Avison 1%+0.1%Adults: Apply twice daily to the affected area and rub on the skin gently with the finger. Continue the applications for 14 days or as directed by the doctor.Children: Suitable for topical application to children.For topical administration only.Dosage of Avison 1%+0.1%Adults: This cream should be applied sparingly to the skin lesion no more than 2 times daily, preferably once in the morning and once in the evening. This cream should not be applied with an occlusive dressing, or to large areas of skin on the body. The duration of treatment with this cream should continue until the inflammatory symptoms subside but not longer than 2 weeks; after 2 weeks of therapy with this cream, continue therapy as needed with a preparation containing econazole or econazole nitrate alone.Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight. Caution should be exercised.Interaction of Avison 1%+0.1%Econazole: compound metabolized by CYP3A4/2C9 oral anticoagulants (warfarin & acenocoumarol).Triamcinolone: lowering of plasma salicylates levels. Increased risk of Gl bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of Hyperkalemia with amphotericin B, beta-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin.ContraindicationsThis Cream is contraindicated- In individuals who have shown hypersensitivity to any of its ingredients. Like any other dermatological preparation containing corticosteroids, this Cream is contraindicated in specific skin conditions such as tuberculous, varicella, herpes simplex or other viral infections of the skin, or fresh vaccination sites. Decubitus ulcers: Viral, bacterial or fungal skin infections (e.g. tuberculosis of the skin, syphilis of the skin, herpes simplex, herpes zoster, chickenpox). Rosacea and rosacea-like dermatitis. Side Effects of Avison 1%+0.1%Rarely, transient local mild irritation, itching & redness may occur immediately after application. Econazole has the minimal allergenic effect and is well tolerated, even by delicate skin. Adrenal suppression on long term continuous topical steroid therapy may occur, particularly in infants or children, or when occlusive dressings are applied. It should be noted that an infant's napkin may act as an occlusive dressing.Pregnancy & LactationPregnancy: Not the Econazole but the Triamcinolone Acetonide crosses the placenta and topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established. However, topical steroids in large amounts or for prolonged periods should not be used in pregnancy.Lactation: Negligible amount of econazole and to some extent Triamcinolone may be excreted in small amounts in breast milk. So, this cream should not be prescribed to the lactating mother or if prescribed lactation should be withheld during treatment.Precautions & Warnings For external use only. This Cream is not for ophthalmic or oral use. If a reaction suggesting hypersensitivity or chemical irritation should occur, use of the medication should be discontinued. Corticosteroids applied to the skin can be absorbed in sufficient amounts to produce systemic effects, including adrenal suppression. Systemic absorption may be increased by various factors such as application over a large skin surface area, application to damaged skin, application under occlusive skin dressings and prolonged duration of therapy. Topical corticosteroids are associated with skin thinning and atrophy, striae, telangiectasis and purpura. Topical corticosteroids may lead to increased risk of dermatological superinfection or opportunistic infection. Children: Increased caution is required when treating children. Compared to adults, the nature of a child's skin and the larger skin surface area relative to body weight may lead to an increased absorption of the corticosteroid via the child's skin. This cream should be used in children only for short periods of time (less than 2 weeks) and on small areas (less than 10% of body surface area).Visual disturbance may be associated with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR).Overdose Effects of Avison 1%+0.1%This Cream is for cutaneous application only. Corticosteroids applied to the skin, including triamcinolone, can be absorbed in sufficient amounts to produce systemic effects. In the event of accidental ingestion, treat symptomatically. If this cream is accidentally applied to the eyes, wash with clean water or saline and seek medical attention if symptoms persist.Storage ConditionsStore in a cool (below 30?C) and dry place, away from light. Keep out of the reach of children.Drug ClassesTriamcinolone & Combined preparationsPregnancyPregnancy: Not the Econazole but the Triamcinolone Acetonide crosses the placenta and topical administration of corticosteroids during pregnancy can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established. However, topical steroids in large amounts or for prolonged periodsshould not be used in pregnancy.Lactation: Negligible amount of econazole and to some extent Triamcinolone may be excreted in small amounts in breast milk. So this cream should not be prescribed to the lactating mother or if prescribed lactation should be withheld during treatment.

Dexlion 30 mgHealing of Erosive Esophagitis: Dexlion 30 mg is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.Maintenance of Healed Erosive Esophagitis: Dexlion 30 mg is indicated to maintain healing of EE and relief of heartburn ... Read moreHealing of Erosive Esophagitis: Dexlion 30 mg is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.Maintenance of Healed Erosive Esophagitis: Dexlion 30 mg is indicated to maintain healing of EE and relief of heartburn for up to 6 months.Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlion 30 mg is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.Theropeutic ClassProton Pump InhibitorPharmacologyDexlion 30 mg delayed-release capsule is a Proton Pump Inhibitor (PPI), that inhibits gastric acid secretion. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). This is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. Dexlion 30 mg capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles.Dexlion 30 mg is a PPI that suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlion 30 mg blocks the final step of acid production.Dosage of Dexlion 30 mgDexlion 30 mg dosing recommendations- Maintenance of Healed erosive esophagitis and relief of heartburn: 30 mg Once daily Symptomatic Non-Erosive GERD: 30 mg Once daily for 4 weeks Healing of erosive esophagitis: 60 mg Once daily for up to 8 weeks Administration of Dexlion 30 mgDexlion 30 mg can be taken without regard to food. It should be swallowed whole. Alternatively, Dexlion 30 mg capsules can be administered as follows: Open capsule Sprinkle intact granules on one tablespoon Swallow immediately. Granules should not be chewed.If a capsule is missed at its usual time, it should be taken as soon as possible. But if it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.Interaction of Dexlion 30 mgWith medicine: Atazanavir, Warfarin, Tacrolimus, Clopidogrel & Methotrexate. With food & others: No data available.ContraindicationsDexlion 30 mg is contraindicated in patients with known hypersensitivity to any component of the formulation.Side Effects of Dexlion 30 mgCommon side effects: Diarrhea, abdominal pain, nausea, vomiting & flatulence.Pregnancy & LactationThere are no adequate or well-controlled studies in pregnant women with Dexlion 30 mg. Exposure in clinical trials was very limited. Dexlion 30 mg should not be administered to pregnant women unless the expected benefits outweigh the potential risks. It is not known whether Dexlion 30 mg is excreted in human milk. However, Dexlion 30 mg and its metabolites are excreted in the milk of rats. As many drugs are excreted in human milk, Dexlion 30 mg should not be given to nursing mothers unless its use is consideredPrecautions & WarningsGastric Malignancy, Clostridium difficile Associated Diarrhea, Bone fracture, Hypomagnesemia, and concomitant use of Dexlion 30 mg with Methotrexate.Overdose Effects of Dexlion 30 mgThere have been no reports of a significant overdose of Dexlion 30 mg. Multiple doses of Dexlion 30 mg 120 mg and a single dose of Dexlion 30 mg 300 mg did not result in death or other severe adverse events.Storage ConditionsStore below 30?C temperature & in a dry place, protected from light. Keep all medicines out of reach of children.Use In Special PopulationsGeriatrics: No dosage adjustment is necessary for elderly patients.Pediatrics: Safety and effectiveness of Dexlion 30 mg in patients below 12 years age have not been established yet.Renal Impairment: No dosage adjustment is necessary for patients with renal impairment.Hepatic Impairment: No adjustment of Dexlion 30 mg is necessary for patients with mild hepatic impairment. A maximum daily dose of 30 mg for patients with moderate hepatic impairment may be considered.Drug ClassesProton Pump InhibitorMode Of ActionDexlion 30 mg delayed-release capsule is a Proton Pump Inhibitor (PPI) which suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlion 30 mg blocks the final step of acid production. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). Dexlion 30 mg is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. This capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles. The dual delayed release formulation in Dexlion 30 mg, plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. After oral administration, mean Cmax and AUC value of Dexlion 30 mg increased approximately dose proportionally. Dexlion 30 mg is extensively metabolized in the liver and excreated by urine.PregnancyPregnancy Category B. There is no adequate and well-controlled studies with Dexlion 30 mg in pregnant women. There is no adequate and well-controlled studies with Dexlion 30 mg in Lactating mother.Pediatric UsesUse in children & adolescents: Safety and effectiveness of Dexlion 30 mg in patients below 12 years age have not been established.Geriatric use: No dose adjustment is necessary for elderly patients.Renal impairment: No dose adjustment of Dexlion 30 mg is necessary for patients with renalimpairment.Hepatic impairment: No dose adjustment for Dexlion 30 mg is necessary for patients with mild hepatic impairment. A maximum daily dose of Dexlion 30 mg 30 mg should be considered for patients with moderate hepatic impairment.

Eprel 50 mgImprovement of muscular hypertonic symptoms in the following diseases Cervical syndrome, periarthritis of the shoulder, lumbago. Spastic paralysis in the following disease: Cerebrovascular disease,spastic spinal paralysis, cervical spondylosis, postoperative sequelae (including cerebrospinal tumor) ... Read moreImprovement of muscular hypertonic symptoms in the following diseases Cervical syndrome, periarthritis of the shoulder, lumbago. Spastic paralysis in the following disease: Cerebrovascular disease,spastic spinal paralysis, cervical spondylosis, postoperative sequelae (including cerebrospinal tumor), sequelae to trauma (spinal trauma, head injury), amyotrophic lateral sclerosis, cerebral palsy, spinocerebellar degeneration, spinal vascular diseases and other encephalomyelopathies.Theropeutic ClassCentrally acting Skeletal Muscle RelaxantsPharmacologyEperisone is centrally-acting skeletal muscle relaxant used to improve myotonic symptoms.Dosage & Administration of Eprel 50 mgFor adults: Usually 3 tablets per day in three divided doses after each meal. The dosage should be adjusted depending on the patient age and severity of symptoms.Dosage of Eprel 50 mgFor adults: Usually 3 tablets per day in three divided doses after each meal. The dosage should be adjusted depending on the patient age and severity of symptoms.Interaction of Eprel 50 mgAvoid concomitant use with tolperisone HCl and methocarbamol.ContraindicationsEperisone is contraindicated in patients with a history of hypersensitivity to Eprel 50 mg.Side Effects of Eprel 50 mgThe side effects of Eperisone are very rare, only a few cases have been observed. These are excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhea, vomiting, indigestion, GI disturbances, insomnia, headache, constipation, etc.Pregnancy & LactationEperisone should only be used in pregnant women if the expected therapeutic benefits are evaluated to outweight the possible risks of treatment. The safety of Eperisone has not been established in pregnant women. The drug should not be used during lactation.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesCentrally acting Skeletal Muscle RelaxantsMode Of ActionEperisone is centrally-acting skeletal muscle relaxant used to improve myotonic symptoms.PregnancyEperisone should only be used in pregnant women if the expected therapeutic benefits are evaluated to outweight the possible risks of treatment. The safety of Eperisone has not been established in pregnant women. The drug should not be used during lactation.

Fostat 40 mgFostat 40 mg is indicated for the chronic management of hyperuricemia in patients with gout. Fostat 40 mg is not recommended for the treatment of asymptomatic hyperuricemia.Theropeutic ClassDrugs used in GoutPharmacologyFostat 40 mg is a non-purine, selective xanthine oxidase (XO) inhibitor. It decreases serum uric acid level by inhibiting xanthine oxidase, which is responsible for uric acid production. Xanthine oxidase breaks down hypoxanthine to xanthine and thus to uric acid. Fostat 40 mg is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.Dosage & Administration of Fostat 40 mgFostat 40 mg is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Fostat 40 mg is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, Fostat 40 mg 80 mg is recommended. Fostat 40 mg can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Fostat 40 mg to patients with mild to moderate renal or hepatic impairment.Dosage of Fostat 40 mgFostat 40 mg is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Fostat 40 mg is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, Fostat 40 mg 80 mg is recommended. Fostat 40 mg can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Fostat 40 mg to patients with mild to moderate renal or hepatic impairment.Interaction of Fostat 40 mgConcomitant administration of Fostat 40 mg with azathioprine, mercaptopurine or theophylline could increase plasma concentrations of these drugs resulting in severe toxicity.ContraindicationsFostat 40 mg is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.Side Effects of Fostat 40 mgThe most common adverse events associated with the use of Fostat 40 mg may include liver function abnormalities, nausea, arthralgia, and rash.Pregnancy & LactationPregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Fostat 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Caution should be exercised when Fostat 40 mg is administered to a nursing woman.Precautions & WarningsGout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Fostat 40 mg. If a gout flare occurs during treatment, Fostat 40 mg need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial for up to six months.Cardiovascular Events: A higher rate of cardiovascular thromboembolic events was observed in patients treated with Fostat 40 mg than allopurinol in clinical trials. Monitor for signs and symptoms of MI and stroke.Liver Enzyme Elevation: Transaminase elevations have been observed in Fostat 40 mg -treated patients. Monitor liver function tests periodically.Overdose Effects of Fostat 40 mgFebustat was studied in healthy subjects in doses up to 300 mg daily for seven days without evidence of dose-limiting toxicities.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Use In Special PopulationsPediatric Use: Safety and effectiveness in pediatric patients under 18 years of age have not been establishedDrug ClassesDrugs used in GoutMode Of ActionFostat 40 mg is a non-purine, selective xanthine oxidase (XO) inhibitor. It decreases serum uric acid level by inhibiting xanthine oxidase, which is responsible for uric acid production. Xanthine oxidase breaks down hypoxanthine to xanthine and thus to uric acid. Fostat 40 mg is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.PregnancyPregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Fostat 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Caution should be exercised when Fostat 40 mg is administered to a nursing woman.Pediatric UsesPediatric Use: Safety and effectiveness in pediatric patients under 18 years of age have not been established

Frulac 20 20 + 50 mgFrusemide & Spironolactone combination is indicated in- Essential hypertension Chronic congestive heart failure Hepatic cirrhosis, with collection of fluid in the abdominal cavity (ascites) Swelling due to excess fluid retention (edema) Hyperaldosteronism Resistant edema associated with secondary hyperaldosteronism Theropeutic ClassPotassium-sparing diuretics, Potassium-sparing diuretics & Aldosterone antagonistsPharmacologySpironolactone (potassium sparing diuretic) and Furosemide (loop diuretic) have different but complementary mechanisms and sites of action. Therefore, when given together they produce additive or synergistic diuretic. The Furosemide component inhibits the Na+/K+/2Cl- co-transporter in the ascending Loop of Henle and blocks the reabsorption of sodium, potassium and chloride ions; thereby increasing the quantity of sodium and the volume of water excreted in the urine. This characteristically induces potassium loss. The spironolactone component inhibits the reabsorption of sodium in exchange for potassium at the distal tubule by antagonising the action of aldosterone so that sodium excretion is greatly favoured and the excess loss of potassium, induced by the Furosemide, is reducedDosage & Administration of Frulac 20 20 + 50 mgFurosemide 20 and spironolactone 50 mg: 1 to 4 tablets daily (20 to 80 mg of Furosemide and 50 to 200 mg of spironolactone) according to the patient?s response.Furosemide 40 and spironolactone 50 mg: For previously stabilized patients requiring higher dosage of spironolactone and Furosemide, This tablet can be used at a dose of one to two tablets daily (Furosemide 40 to 80 mg and spironolactone 50 to 100 mg).Dosage of Frulac 20 20 + 50 mgFurosemide 20 and spironolactone 50 mg: 1 to 4 tablets daily (20 to 80 mg of Furosemide and 50 to 200 mg of spironolactone) according to the patient?s response.Furosemide 40 and spironolactone 50 mg: For previously stabilized patients requiring a higher dosage of spironolactone and Furosemide, This tablet can be used at a dose of one to two tablets daily (Furosemide 40 to 80 mg and spironolactone 50 to 100 mg).Use in children:?Spironolactone and Furosemide is not suitable for use in children. Spironolactone and Furosemide may both be excreted more slowly in the elderly.Interaction of Frulac 20 20 + 50 mgWhen taken together with ACE inhibitors or potassium salts there is an increased risk of hyperkalemia. Spironolactone increases the levels of cardiac glycosides such as digoxin in the blood and this may result in digitalis toxicity. Corticosteroids may cause hypokalemia if they are used with Spironolactone. The blood pressure lowering and diuretic effects of Furosemide may be reduced or abolished when used together with indomethacin and possibly other non-steroidal anti-inflammatory drugs (NSAIDs). Furosemide may increase the ototoxicity of aminoglycoside antibiotics. Simultaneous administration of sucralfate and Furosemide may reduce the natriuretic and anti-hypertensive effect of Furosemide.ContraindicationsContraindicated in patients with anuria, acute renal insufficiency, rapidly deteriorating or severe impairment of renal function (creatinine clearance <30 ml/min), hyperkalaemia, Addison's disease and in patients who are hypersensitive to Spironolactone, Furosemide or sulphonamides.Side Effects of Frulac 20 20 + 50 mgSpironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. Ataxia, mental confusion, and skin rashes have been reported as side effect. Gynaecomastia is not uncommon and in rare cases breast enlargement may persist. Other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. Transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. Spironolactone may cause hyponatremia and hyperkalemia. Excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. Serious depletion of potassium and magnesium may lead to cardiac arrhythmias.Pregnancy & LactationPregnancy: Spironolactone and its metabolites may cross the placental barrier. The use of spironolactone in pregnant women requires that the anticipated benefit be weighed against the possible hazards to the mother and fetus. Animal teratology studies indicate that Furosemide may cause fetal abnormalities. Therefore, Furosemide should only be used in women in child bearing age when appropriate contraceptive measures are taken or if the potential benefits justify the potential risks to the fetus.Lactation: Metabolites of Spironolactone have been detected in breast milk. If use of Spironolactone is considered essential, an alternative method of infant feeding should be instituted. Furosemide is excreted in breast milk and breast-feeding should be discontinued if treatment is essential.Precautions & WarningsCaution should be taken in patients liable to electrolyte deficiency. This preparation should also be used with caution in diabetes, enlarged prostate, hypotension and in hypovolemia.Overdose Effects of Frulac 20 20 + 50 mgSymptoms of overdosage include drowsiness, mental confusion, dizziness, diarrhea and vomiting etc. due to excessive diuresis. Treatment should be aimed at the replacement of fluid and correction of any electrolyte imbalance.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Use In Special PopulationsUse in children: Spironolactone and Furosemide is not suitable for use in children. Spironolactone and Furosemide may both be excreted more slowly in the elderly.Drug ClassesPotassium-sparing diuretics, Potassium-sparing diuretics & Aldosterone antagonistsMode Of ActionSpironolactone (potassium sparing diuretic) and Furosemide (loop diuretic) have different but complementary mechanisms and sites of action. Therefore, when given together they produce additive or synergistic diuretic. The Furosemide component inhibits the Na+/K+/2Cl- co-transporter in the ascending Loop of Henle and blocks the reabsorption of sodium, potassium and chloride ions; thereby increasing the quantity of sodium and the volume of water excreted in the urine. This characteristically induces potassium loss. The spironolactone component inhibits the reabsorption of sodium in exchange for potassium at the distal tubule by antagonising the action of aldosterone so that sodium excretion is greatly favoured and the excess loss of potassium, induced by the Furosemide, is reducedPregnancyPregnancy: Spironolactone and its metabolites may cross the placental barrier. The use of spironolactone in pregnant women requires that the anticipated benefit be weighed against the possible hazards to the mother and fetus. Animal teratology studies indicate that Furosemide may cause fetal abnormalities. Therefore, Furosemide should only be used in women in child bearing age when appropriate contraceptive measures are taken or if the potential benefits justify the potential risks to the fetus.Lactation: Metabolites of Spironolactone have been detected in breast milk. If use of Spironolactone is considered essential, an alternative method of infant feeding should be instituted. Furosemide is excreted in breast milk and breast-feeding should be discontinued if treatment is essential.

Losan 50 mgHypertension: It is recommended to use Losan 50 mg to treat hypertension. It could be used with other antihypertensive medications or taken alone (eg. thiazide diuretics). Renal Protection in Type-2 Diabetic Patients with Proteinuria: In hypertensive type-2 diabetics with proteinuria, which is defined as urine albumin to creatinine ratio >300 mg/g, Losan 50 mg is advised to postpone the advancement of renal disease.Theropeutic ClassAngiotensin-ll receptor blockerPharmacologyThe first angiotensin II receptor blocker that is orally active without a peptide is Losan 50 mg. It binds to the AT1 receptor, which is present in numerous tissues (such as the heart, kidneys, adrenal glands, and vascular smooth muscle), and inhibits several critical biological processes, such as vasoconstriction and the production of the hormone aldosterone that causes hypertension.Dosage & Administration of Losan 50 mgFor the majority of patients, the beginning and maintenance dose is 50 mg once daily. Prior to raising the dose, 25 mg twice daily is advised if the antihypertensive impact of 50 mg once daily is insufficient. A starting dose of 25 mg once daily should be taken into consideration for individuals with intravascular volume depletion (such as those on high-dose diuretics). One or two doses of Losan 50 mg can be given each day. From 25 mg to 100 mg is the range for the total daily dose.Dosage of Losan 50 mgFor the majority of patients, the beginning and maintenance dose is 50 mg once daily. Prior to raising the dose, 25 mg twice daily is advised if the antihypertensive impact of 50 mg once daily is insufficient. A starting dose of 25 mg once daily should be taken into consideration for individuals with intravascular volume depletion (such as those on high-dose diuretics). One or two doses of Losan 50 mg can be given each day. From 25 mg to 100 mg is the range for the total daily dose.Interaction of Losan 50 mgLevels of the Losan 50 mg active metabolite are decreased by rifampicin and fluconazole. The antihypertensive effects of hydrochlorothiazide and Losan 50 mg used together may be potentiated. Increases in serum potassium may result from the concurrent use of potassium-sparing diuretics (such as spironolactone, triamterene, and amiloride), potassium supplements, or salt substitutes containing potassium. The non-steroidal anti-inflammatory medicine indomethacin may lessen the antihypertensive effects of losartan. The risk of renal impairment is increased by the concurrent use of an ACE inhibitor, an angiotensin receptor antagonist, an anti-inflammatory medication, and a thiazide diuretic.ContraindicationsPregnant women and individuals who are hypersensitive to any ingredient in this medication should not use Losan 50 mg. Those with diabetes shouldn't take Aliskiren and Losan 50 mg together.Side Effects of Losan 50 mgLosan 50 mg side effects are minor and short-lived in nature. Dizziness, diarrhea, nasal congestion, coughing, and upper respiratory infections are the most frequent adverse effects. Fatigue, oedema, chest pain, nausea, headaches, and pharyngitis are other adverse effects.Pregnancy & LactationCategory D for pregnancies. If Losan 50 mg is given during the second or third trimester of pregnancy, the risk to the fetus increases. Given that numerous medicines are excreted in human milk and that it is unknown whether Losan 50 mg is one of them, a choice should be taken regarding whether to stop breastfeeding or stop taking the medication, taking into account the significance of the medication to the mother.Precautions & WarningsIn addition to increasing fetal and neonatal morbidity and mortality, the use of Losan 50 mg throughout the second and third trimesters of pregnancy decreases fetal renal function. Symptomatic hypotension may happen in people who are intravascularly volume-depleted (such as those taking high-dose diuretics). Patients with cirrhosis have a considerably higher plasma concentration of Losan 50 mg. Patients with renal impairment have experienced changes in renal function, including renal failure.Storage ConditionsKeep dry and away from heat and light. Keep out of children's reach.Drug ClassesAngiotensin-ll receptor blockerMode Of ActionThe first angiotensin II receptor blocker that is orally active without a peptide is Losan 50 mg. It binds to the AT1 receptor, which is present in numerous tissues (such as the heart, kidneys, adrenal glands, and vascular smooth muscle), and inhibits several critical biological processes, such as vasoconstriction and the production of the hormone aldosterone that causes hypertension.PregnancyCategory D for pregnancies. If Losan 50 mg is given during the second or third trimester of pregnancy, the risk to the fetus increases. Given that numerous medicines are excreted in human milk and that it is unknown whether Losan 50 mg is one of them, a choice should be taken regarding whether to stop breastfeeding or stop taking the medication, taking into account the significance of the medication to the mother.

Miki-H 2%+1%For the topical treatment of inflamed dermatoses where? infection by susceptible organisms and inflammation coexist e.g. intertrigo and infected eczema. For moist or dry eczema or dermatitis including atopic eczema, primary irritant or contact allergic eczema or seborrheic eczema including that ... Read moreFor the topical treatment of inflamed dermatoses where? infection by susceptible organisms and inflammation coexist e.g. intertrigo and infected eczema. For moist or dry eczema or dermatitis including atopic eczema, primary irritant or contact allergic eczema or seborrheic eczema including that associated with acne. Also for interiginous eczema including inflammatory interigo, perianal and genital dermatitis. Organisms which are?susceptible to miconazole are dermatophytes and pathogenic yeasts (e.g. Candida spp.): also many Gram-positive bacteria including many strains of Streptococcus and Staphylococcus.Theropeutic ClassHydrocortisone & Combined preparationsPharmacologyMiconazole nitrate is an imidazole antifungal agent and possesses antibacterial activity. At low concentrations, it interacts with fungal cytochrome P450 which results in inhibition of a demethylation step in the biosynthesis of ergosterol. At high concentrations, miconazole interacts with membrane lipids causing direct membrane damage which results in leakage of fungus cell constituents. It appears that fungistatic effects result from the inhibition of membrane sterol synthesis and membrane. Hydrocortisone is a naturally occurring glucocorticoid that is now prepared by chemical synthesis and its main action is to reduce the response of the skin to injury (i.e. anti-inflammatory). It also has immunosuppressant and antimitotic actions. The anti-inflammatory activity of hydrocortisone is its main therapeutic property. This is thought to be mediated by the reduction in formation, release and action of the various vasoactive chemicals release during inflammation-kinins, histamine, lysosomal enzymes, prostaglandins and the complement system. Steroids decrease membrane permeability and bind to tissue receptors. They also induce vasoconstriction, by reducing vascular permeability and reversing vascular dilation which in turn decreases serum extravasation, swelling and discomfort, including itching. Thus, they effectively reduce cellular access to inflamed sites. Corticosteroids also exhibit an antimitotic effect against human epidermal cells which may account for their effectiveness in the treatment of scaly dermatoses such as psoriasis.Dosage & Administration of Miki-H 2%+1%It should be applied topically to the affected area two or three times daily. The same dosage applies to both adults and children. In infants, long term continuous topical corticosteroid therapy should be avoided. Occlusive dressing is usually only necessary in the case of nail lesions. Once the inflammatory symptoms have disappointed (after about 7 days) treatment can be continued where necessary with this cream.Dosage of Miki-H 2%+1%Apply to the affected area as a thin film two or four times daily for 1 to 2 weeks. Rub it well with your finger until this cream fully vanished on the skin. Treatment should be continued at least one week after the disappearance of all signs and symptoms. The same dosage applies to both adults and children.Interaction of Miki-H 2%+1%Amphotericin antagonizes the activity of Miconazole.ContraindicationsIt is contraindicated in individuals who are hypersensitive to it or any of its components. Should not be used in pregnant mother and lactating mother without physician's advice.Side Effects of Miki-H 2%+1%Rarely local sensitivity may occur. Long term use may decrease in the production of natural hormones by the adrenal gland.Pregnancy & LactationAdministration of corticosteroids to pregnant animal at high doses can cause abnormalities of fetal development. Topical steroids should not be extensively used in pregnancy.Precautions & WarningsTo be dispensed only on the prescription of a registered physician. Keep out of reach of children. Take care or consult with a physician in case of use in children and elderly people for long-term use.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesHydrocortisone & Combined preparationsMode Of ActionMiconazole is a substituted imidazole, is one of the family of azoles useful in treating the superficial candidiasis and of the skin infections dermatophytosis and pityriasis versicolor, acanthameaba, seborrhoic dermatitis. Also active against Aspergillus spp., Cryptococcus neoformans, Pseudalescheria boydii and some gram-positive bacteria including Staphylococci and Streptococci. Hydrocortisone is a naturally occurring glucocorticoid that's now prepared synthetically. Its important function is in the skin injury such as inflammation. Also it has antipruritic, antimycotic and vasoconstrictive activity.Miconazole is imidazole antifungal agents that interfere with ergosterol synthesis and therefore alters the permeability of the cell membrane of sensitive fungi. Thus causes the killing of fungi, when applied to the skin, Hydrocortisone is absorbed into the skin cells. It prevents the release of certain chemicals, which is responsible for inflammation. Thus hydrocortisone reduces inflammation.PregnancyAdministration of corticosteroids to pregnant animal at high doses can cause abnormalities of fetal development. Topical steroids should not be extensively used in pregnancy.